Ablative therapies in renal cell carcinoma

Area of Science:

• Urology
• Oncology
• Minimally Invasive Surgery

Background:

• Renal cell carcinoma (RCC) management often involves surgical excision.
• Ablative therapies present an alternative for specific patient populations.
• Technological advancements have improved ablative techniques for RCC.

Purpose of the Study:

• To review the current use and outcomes of ablative therapies for renal cell carcinoma.
• To compare ablative therapies with traditional surgical excision.
• To identify patient and tumor characteristics influencing outcomes.

Main Methods:

• PubMed search for English-language literature on "ablation" and "renal carcinoma."
• Review of articles focusing on technological advancements and clinical outcomes.
• Selection of pertinent studies for analysis.

Main Results:

• Intermediate-term oncologic outcomes for cryoablation and radiofrequency ablation are acceptable but inferior to surgical excision.
• Ablative therapies demonstrate decreased morbidity, lower complication rates, and preserved renal function compared to surgery.
• Percutaneous ablation is more cost-effective and causes less perinephric desmoplasia than laparoscopic approaches.

Conclusions:

• Careful patient and tumor selection is crucial for successful ablative therapy outcomes.
• Diagnostic biopsy is mandatory for confirmation, with post-therapy biopsy considered for recurrence concerns.
• Ablation is a viable option for small, biopsy-confirmed renal cell carcinomas in patients ineligible for surgery, though long-term efficacy is not yet established.